Showing results (171-180 of 341) with videos related to

Sort By:
Pageof 35
JACC. Cardiovascular Interventions|November 21, 2015
Diagnostic and Prognostic Implications of Coronary Flow Capacity: A Comprehensive Cross-Modality Physiological Concept in Ischemic Heart DiseaseTim P van de Hoef, Mauro Echavarría-Pinto, Martijn A van Lavieren, et al.
Diabetes Care|May 13, 2011
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) studyMichael R MacDonald, Mark C Petrie, Philip D Home, et al.
JACC. Heart Failure|October 11, 2020
Estimating the Lifetime Benefits of Treatments for Heart FailureJoão Pedro Ferreira, Kieran F Docherty, Susan Stienen, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|February 4, 2021
Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR AsiaYong Huo, Frans Van de Werf, Yaling Han, et al.
European Heart Journal|September 30, 2008
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeStuart J Pocock, John J V McMurray, Joanna Dobson, et al.
European Journal of Heart Failure|September 10, 2022
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trialMichael Böhm, Javed Butler, Felix Mahfoud, et al.
European Heart Journal|August 23, 2021
Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trialStuart J Pocock, João Pedro Ferreira, John Gregson, et al.
The American Journal of Cardiology|November 13, 2016
Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse OutcomesMikkel M Schoos, Roxana Mehran, George D Dangas, et al.
Journal of the American College of Cardiology|September 24, 2021
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced TrialJames L Januzzi, Faiez Zannad, Stefan D Anker, et al.
JACC. Heart Failure|October 25, 2024
Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved TrialWolfram Doehner, Stefan D Anker, Javed Butler, et al.
Pageof 35